SinghJASaagKGBridgesSLJr, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016;68:1-25. doi:10.1002/acr.22783.
2.
MazurekGHJerebJVernonA, et al. Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection—United States, 2010. MMWR Recomm Rep. 2010;59:1-25.
3.
Coronavirus Disease2019(COVID-19) Treatment Guidelines [Internet]. Bethesda, MD: National Institutes of Health; 2021-2022.
4.
SantosCSFérnandezXCMoriano MoralesC, et al. Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?RMD Open. 2021;7:e001439. doi:10.1136/rmdopen-2020-001439.
5.
StrangfeldASchäferMGianfrancescoMA, et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021;80:930-942. doi:10.1136/annrheumdis-2020-219498.
6.
MehtaPGasparyanAYZimbaO, et al. Systemic lupus erythematosus in the light of the COVID-19 pandemic: infection, vaccination, and impact on disease management. Clin Rheumatol. 2022;41:2893-2910. doi:10.1007/s10067-022-06227-7.
7.
NakajimaRSakaiFMimuraT, et al. Acute- or subacute-onset lung complications in treating patients with rheumatoid arthritis. Can Assoc Radiol J. 2013;64:200-207. doi:10.1016/j.carj.2011.12.017.
8.
HallowellRWHortonMR. Interstitial lung disease in patients with rheumatoid arthritis: spontaneous and drug induced. Drugs. 2014;74:443-450. doi:10.1007/s40265-014-0190-z.
9.
SparksJAWallaceZSSeetAM, et al. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry. Ann Rheum Dis. 2021;80:1137-1146. doi:10.1136/annrheumdis-2021-220418.
10.
NaranjoCABustoUSellersEM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245. doi:10.1038/clpt.1981.
